AzTrials
AzTrials

PolytraumaPhase 4NCT07480655

Pv-aCO₂ Gap-Guided Resuscitation in Adult Polytrauma Patients: A Prospective Randomized Controlled Trial

A Phase 4 study testing Veno-arterial Carbondioxide gap and Conventional resuscitation end points in people with Polytrauma and Resuscitation, Trauma Patients, run by Pakistan Institute of Medical Sciences at 1 site in Pakistan.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

dult patients with multiple traumatic injuries admitted to the ICU from the operating room, emergency department, or hospital wards who meet the study criteria will be included after obtaining informed consent from the patient or their legal guardian. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Polytrauma, Resuscitation, Trauma Patients
What is being tested?
Veno-arterial Carbondioxide gap and Conventional resuscitation end points
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 sitePakistan
Study dates
16 Mar 2026to 16 Jun 2026
Phase
Phase 4
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Either Gender
  • Poly-trauma patients
  • ○ Both penetrating and blunt trauma
  • Both surgical and non-surgical
  • Shock States

Who cannot join

  • Any Chest trauma
  • Patients with Obstructive and restrictive lung disease
  • Obstructive sleep apnea
  • Septic shock
  • Pregnant patients
  • Patients who will require readmission within 48 h after step-down from the ICU.
  • Patients who will need extra-corporeal membrane oxygenation support

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Muhammad Haroon Anwar, MBBS contact

+92-333-5236956

haroonanwar22@gmail.com

Pakistan1 site, 1 recruiting
  • Department of Anesthesia, Pakistan Institute of Medical Sciences

    Islamabad, Federal, 44000

    Naheed Fatima, MBBS,FCPS, +92-300-5236655, naheedfk73@gmail.com

    Recruiting

Other trials in Pakistan

About this study

Official title: Evaluation of Effect of Pv-aCO2-Gap on Clinical Outcomes With Standard Resuscitation End-points in Adult Poly-trauma Patients Admitted to the ICU --- Prospective Randomized Control Trial

dult patients with multiple traumatic injuries admitted to the ICU from the operating room, emergency department, or hospital wards who meet the study criteria will be included after obtaining informed consent from the patient or their legal guardian. Participants will be randomly divided into two groups: one group will receive treatment guided by the difference between carbon dioxide levels in venous and arterial blood, while the other group will receive treatment based on standard resuscitation parameters commonly used in critical care. As part of routine monitoring, all patients will have a central venous catheter and an arterial line inserted to measure blood parameters. Blood samples from both lines will be taken shortly after ICU admission and at regular intervals during the first three days. These samples will be analyzed using a bedside blood gas machine, and the results will be compared between the two groups to determine whether monitoring the difference in carbon dioxide levels between venous and arterial blood improves patient outcomes compared with standard care.

Read the detailed description

All polytrauma patients admitted to the ICU from the operating theater, emergency department, or hospital wards who fulfill the inclusion criteria will be enrolled in the study after obtaining written informed consent from the patients or their legal representatives. Participants will be randomized in a 1:1 ratio using a computer-generated method into two groups: an intervention group managed with a Pv-aCO₂ gap-targeted approach and a control group managed according to standard resuscitation end-points. As part of routine hemodynamic monitoring in critical care, a central venous catheter (two- or three-lumen catheter-Arrow) and an arterial catheter (Arterial Leader Cath-Vygon or Teleflex) will be inserted in all participants before or immediately after ICU admission. After insertion, the position of the central venous catheter tip at the junction of the superior vena cava and right atrium will be confirmed by chest X-ray. Arterial and venous blood samples for blood gas analysis (ABGA and VBGA) will be obtained in the ICU using a point-of-care gas analyzer (ABL800 FLEX®, Radiometer) within 1 hour of ICU admission and subsequently at 6, 12, 24, 48, and 72 hours. The time interval between arterial and venous blood sampling will be kept under 5 minutes to minimize bias, and the measurements obtained at different time points will be compared with standard resuscitation end-points.

Being tested
Veno-arterial Carbondioxide gap, Conventional resuscitation end points
Keywords
Veno-arterial carbondioxide gap, Polytrauma resuscitation
Medical subject headings
Multiple Trauma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Veno-arterial Carbondioxide gapDiagnostic test

    Arterial and central venous blood samples will be obtained for blood gas analysis using a point-of-care blood gas analyzer (ABL800 FLEX®, Radiometer). Sampling will be performed within 1 hour of ICU admission and subsequently at 6, 12, 24, 48, and 72 hours during the ICU stay. The measurements will be used to assess arterial and venous blood gas parameters for monitoring and guiding patient management.

  • Conventional resuscitation end pointsDiagnostic test

    Patients in this group will be managed using standard resuscitation parameters, including monitoring of arterial base deficit, arterial pH, serum lactate levels, and bicarbonate levels. These parameters will be measured through arterial blood gas analysis within 1 hour of admission to the ICU and subsequently at 6, 12, 24, 48, and 72 hours during the ICU stay, and will be used to guide ongoing resuscitation and clinical management.

Study groups in NCT07480655
Study groupRoleWhat they receive
Carbondioxide gap groupExperimentalNot described
Receives: Diagnostic Test: Veno-arterial Carbondioxide gap
Conventional resuscitation groupActive comparatorNot described
Receives: Diagnostic Test: Conventional resuscitation end points

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Length of mechanical ventilation

    Measured: This will be the number of days of ventilatory support once patient is admitted to ICU

Secondary outcomes (3)
  1. ICU stay

    Measured: This will the total length of ICU stay measured in number of days

  2. ICU Mortality

    Measured: This will be the death occurring during ICU stay

  3. qSOFA score

    Measured: This will be measured at time of admission in ICU then at 48h and 72h following admission

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Mar 2026
  2. Study start16 Mar 2026 (estimated)
  3. Primary completion16 Jun 2026 (estimated)
  4. Study completion16 Jun 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07480655
Sponsor's protocol ID
F5.2/2024(ERRC)/PIMS
Status last verified
Mar 2026
First submitted
15 Mar 2026
Last updated
18 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Hospital Ethical committee doesnt allow data sharing

Publications

  • Doppmann P, Meuli L, Sollid SJM, Filipovic M, Knapp J, Exadaktylos A, Albrecht R, Pietsch U. End-tidal to arterial carbon dioxide gradient is associated with increased mortality in patients with traumatic brain injury: a retrospective observational study. Sci Rep. 2021 May 17;11(1):10391. doi: 10.1038/s41598-021-89913-x.

    PubMed 34001982

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Veno-arterial Carbondioxide gap and Conventional resuscitation end points in people with Polytrauma and Resuscitation, Trauma Patients, run by Pakistan Institute of Medical Sciences at 1 site in Pakistan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 18 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Muhammad Haroon Anwar, MBBS (+92-333-5236956, haroonanwar22@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Length of mechanical ventilation (time frame: This will be the number of days of ventilatory support once patient is admitted to ICU). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07480655, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in